This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

This product is a synthetic antibacterial anti-tuberculosis drug that can penetrate into mycobacteria to interfere with RNA synthesis, thereby inhibiting bacterial reproduction. It is only effective against mycobacteria in the growth and reproduction period. So far, no cross-resistance has been found between this product and other anti-tuberculosis drugs.

This product is a dibenzodiazepine antipsychotic. It has a strong blocking effect on the 5-hydroxytryptamine (5-HT2A) receptor and dopamine (DA1) receptor in the brain, and also has a blocking effect on the dopamine (DA4) receptor, and a weaker blocking effect on the dopamine (DA2) receptor. In addition, it also has anticholinergic (M1), antihistamine (H1) and anti-α-adrenaline receptor effects. Extrapyramidal reactions are rare, and generally do not cause an increase in blood prolactin. It can directly inhibit the ascending activation system of the brainstem reticular formation and has a strong sedative and hypnotic effect.

This product is a phenothiazine antipsychotic, and its mechanism of action is mainly related to its blocking of dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways. It has a blocking effect on dopamine (DA1) receptors, 5-hydroxytryptamine receptors, M-type acetylcholine receptors, and α-adrenaline receptors. At low doses, it can inhibit dopamine receptors in the medulla oblongata emetic chemoreceptor area, and at high doses, it can directly inhibit the vomiting center, producing a powerful antiemetic effect. It inhibits the body temperature regulation center, lowering the body temperature, which can change with changes in the external environment. It blocks the action of peripheral α-adrenaline receptors, causing blood vessels to dilate, causing a drop in blood pressure, and also has a certain effect on the endocrine system.

It has a good antibacterial effect on human tuberculosis bacteria, and its bactericidal effect is strongest at pH 5-5.5. It is currently the best bactericidal drug for tuberculosis bacteria that grow slowly in phagocytes in an acidic environment. The antibacterial concentration in vivo is 12.5 mu; g/ml, and 50 mu; g/ml can kill tuberculosis bacteria. The concentration that inhibits tuberculosis bacteria inside cells is 10 times lower than that outside cells, and it has almost no antibacterial effect in neutral and alkaline environments. The mechanism of action may be related to pyrazinoic acid. After pyrazinamide penetrates into phagocytes and enters the tuberculosis bacteria, the amidase in the bacteria removes the amide group and converts it into pyrazinoic acid to exert an antibacterial effect. In addition, because pyrazinamide is similar to nicotinamide in chemical structure, it interferes with dehydrogenase by replacing nicotinamide, prevents dehydrogenation, and hinders the use of oxygen by tuberculosis bacteria, which affects the normal metabolism of bacteria and causes death.